Literature DB >> 12410358

Mode of tumor spread and surgical strategy in gallbladder carcinoma.

Satoshi Kondo1, Yuji Nimura, Junichi Kamiya, Masato Nagino, Michio Kanai, Katsuhiko Uesaka, Naokazu Hayakawa.   

Abstract

BACKGROUND AND AIMS: The mode and degree of tumor spread in gallbladder carcinoma is poorly documented. The present study classifies the patterns of dissemination of this tumor with a focus on surgical strategy. PATIENTS AND METHODS: Surgical specimens from 112 patients who underwent curative resection were reviewed. There were stage I, II, III, and IV in 9, 11, 14, and 78 patients, respectively.
RESULTS: Six types of spread were identified. In the hepatic bed type ( n=20) a large mass in the fundus and body penetrated into the liver through the gallbladder bed with or without contiguous spread to the gastrointestinal tract. The extent of hepatectomy was individualized from wedge resection to extended right hepatectomy based on the clinical findings. In the hepatic hilum type ( n=26) a relatively small tumor in the neck infiltrated the hepatic hilum causing obstructive jaundice. Extended right hepatectomy plus bile duct resection with or without portal vein resection was necessary for curative resection because the tumor had extended into the right portal pedicle, and postoperative hepatic failure was common. In the bed and hilum type ( n=18) a huge mass occupying the entire gallbladder involved both the gallbladder bed and the hepatic hilum. Extended right hepatectomy with combined resection of contiguous spread was necessary for curative resection. In the lymph node type ( n=15) enlarged metastatic lymph nodes were the most prominent feature, and the primary tumor remains limited to the gallbladder in most cases. Extended lymphadenectomy with combined individualized resection was performed. In the cystic duct type ( n=9) a small mass arising from the cystic duct involved the common bile duct. This type presented at an earlier stage than the first four types. In the localized type ( n=24) tumor spread is localized to the gallbladder and presented at the earliest stage of any type. Simple cholecystectomy with or without wedge hepatic resection and regional lymphadenectomy resulted in a satisfactory outcome. Prognosis depends on the stage rather than on the mode of tumor spread. Even in the advanced types favorable results may be obtained in selected patients undergoing radical resection for M0 tumors without portal vein invasion. Success also was achieved in the rare patients with para-aortic lymph node metastases that were not infiltrative.
CONCLUSIONS: These six types of gallbladder cancer can be diagnosed preoperatively by clinical and radiological examination. This information should assist the surgeon in the choice of operation and predict outcome.

Entities:  

Mesh:

Year:  2002        PMID: 12410358     DOI: 10.1007/s00423-002-0318-6

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  27 in total

1.  An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center.

Authors:  Elijah Dixon; Charles M Vollmer; Ajay Sahajpal; Mark Cattral; David Grant; Christopher Doig; Al Hemming; Bryce Taylor; Bernard Langer; Paul Greig; Steven Gallinger
Journal:  Ann Surg       Date:  2005-03       Impact factor: 12.969

2.  Frequent activation of mitogen-activated protein kinase relative to Akt in extrahepatic biliary tract cancer.

Authors:  Hiroshige Hori; Tetsuo Ajiki; Yoshiyasu Mita; Hideki Horiuchi; Kenro Hirata; Taku Matsumoto; Haruki Morimoto; Tsunenori Fujita; Yonson Ku; Yoshikazu Kuroda
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

3.  Ten-year experience in the management of gallbladder cancer from a single hepatobiliary and pancreatic centre with review of the literature.

Authors:  Seok L Ong; Giuseppe Garcea; Sarah C Thomasset; Christopher P Neal; David M Lloyd; David P Berry; Ashley R Dennison
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

4.  Comparison of CT and MRI for presurgical characterization of paraaortic lymph nodes in patients with pancreatico-biliary carcinoma.

Authors:  Young-Chul Kim; Mi-Suk Park; Seung-Whan Cha; Yong-Eun Chung; Joon-Suk Lim; Kyung-Sik Kim; Myeong-Jin Kim; Ki-Whang Kim
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

5.  Should the extrahepatic bile duct be resected or preserved in R0 radical surgery for advanced gallbladder carcinoma? Results of a Japanese Society of Biliary Surgery Survey: a multicenter study.

Authors:  Tatsuo Araida; Ryouta Higuchi; Mie Hamano; Yoshihito Kodera; Nobuhiro Takeshita; Takehiro Ota; Tatsuya Yoshikawa; Masakazu Yamamoto; Ken Takasaki
Journal:  Surg Today       Date:  2009-09-24       Impact factor: 2.549

Review 6.  Gallbladder carcinoma incidentally encountered during laparoscopic cholecystectomy: how to deal with it.

Authors:  Ketao Jin; Huanrong Lan; Tieming Zhu; Kuifeng He; Lisong Teng
Journal:  Clin Transl Oncol       Date:  2011-01       Impact factor: 3.405

7.  Audit of management of gallbladder cancer in a Nigerian tertiary health facility.

Authors:  O I Alatise; O O Lawal; A O Adisa; O A Arowolo; O O Ayoola; E A Agbakwuru; A R K Adesunkanmi; G O Omoniyi-Esan; O O Olaofe
Journal:  J Gastrointest Cancer       Date:  2012-09

8.  Operative approach to gallbladder cancer.

Authors:  Henry A Pitt; Attila Nakeeb
Journal:  Curr Gastroenterol Rep       Date:  2006-04

9.  Simultaneous gallbladder and bile duct cancers: revisiting the pathological possibilities.

Authors:  P J Shukla; S G Barreto; S V Shrikhande; M R Ramadwar; K K Deodhar; S Mehta; P Patil; K M Mohandas
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

10.  Paraaortic lymph node metastasis in patients with intra-abdominal malignancies: CT vs PET.

Authors:  Mi-Jung Lee; Mi Jin Yun; Mi-Suk Park; Seung Hwan Cha; Myeong-Jin Kim; Jong Doo Lee; Ki Whang Kim
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.